BMS-986500 / BMS - LARVOL DELTA

BMS-986500: A novel molecular glue degrader of Cyclin E1 with first-in-class potential for treating CCNE1-amplified cancers and overcoming CDK4/6 inhibitor resistance in HR+ breast cancer (EORTC-NCI-AACR 2026) - "Abstract will be available on the day of the presentation"

Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CCNE1

CA243-0001: A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors (clinicaltrialsregister.eu) - P1 | N=15 | Not yet recruiting | Sponsor: Bristol-Myers Squibb Services Unlimited Company

Monotherapy • New P1 trial • Platinum resistant • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • High Grade Serous Ovarian Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=234 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor